Final Logo-01.png
Creatinine Test Market Size & Share to Exceed USD 6212.9 Million by 2034, at CAGR of 17.4%. “Driving Efficiency in Renal Function Assessment"– By PMI
12 févr. 2024 17h30 HE | PMI
Covina, Feb. 12, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Creatinine Test Market size was valued at about USD 1250.4 Million in 2024 and expected to grow at CAGR of...
Final Logo-01.png
Remicade Biosimilars Market Size & Share to Exceed USD 34.4 Billion by 2034, at CAGR of 9.30% - By PMI
08 févr. 2024 17h30 HE | PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Remicade Biosimilars Market size was valued at about USD 15.3 Billion in 2024 and expected to grow at CAGR of...
UNP
Unnatural Products, Inc. Enters Research Collaboration with Merck
23 janv. 2024 09h00 HE | Unnatural Products
Santa Cruz, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech company pairing AI with chemistry to enable the next generation of molecularly targeted therapeutics,...
logo.png
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
10 janv. 2024 07h26 HE | Arch Biopartners
TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from...
HARP Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Harpoon Therapeutics to Merck
08 janv. 2024 09h25 HE | Wohl & Fruchter LLP
We are investigating the fairness of the sale of Harpoon Therapeutics to Merck for $23.00 per share in cash.
logo.png
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide
21 déc. 2023 07h30 HE | Arch Biopartners
TORONTO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Kocaeli...
ITM_Logo_Claim_RGB_high-res.png
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
14 déc. 2023 09h28 HE | ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens indication areas to...
Final Logo-01.png
[New Report] Pharmaceutical Excipients Market is estimated to be US$ 10.49 billion by 2030 with a CAGR of 5.3% during the forecast period – By PMI
25 mai 2023 12h36 HE | PMI
Covina, May 25, 2023 (GLOBE NEWSWIRE) -- “According to the latest research study, the demand of Pharmaceutical Excipients Market accounted for US$ 6.52 billion 2020 and is estimated to be US$ 10.49...
Proxygen Logo.jpg
Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders
05 avr. 2023 07h00 HE | Proxygen
VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license...
logo-alt.png
Cell Dissociation Market is estimated to be US$ 1097.1 Million by 2032 with a CAGR of 14.2% over the forecast period (2022-2032) - By PMI
05 janv. 2023 09h32 HE | PMI
Covina, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The process of cell dissociation, also known as trypsinization, involves a proteolytic enzyme that helps break down proteins to separate adherent cells from...